ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Shares of ImmunityBio (NASDAQ:IBRX) climbed 6% on Wednesday morning after the company said Saudi Arabia’s Food and Drug ...

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

Use of immune checkpoint inhibitors for cancer was associated with a significant reduction in actinic keratoses in a small study. The effect was greatest in younger patients and those with a history ...

The concept of immunotherapy or boosting the body’s immune system to target tumors was first practically applied in the early ...

Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...

Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...